Sponsor: Rubicon Genomics
Recording Date: 2/19/2014
Recording Time: 1 hour
Miragen Therapeutics' Eva van Rooij discusses microRNA-based therapeutics, the challenges associated with chronic microRNA knockdown, therapeutic microRNA antagonists, and more.
In this video, Julia Karow, Editor of Clinical Sequencing News, interviews Saskia Biskup, CEO of the Center for Genomics and Transcriptomics, or CeGaT, at the company's headquarters in Tübingen, Germany.
In this video, Illumina's CLIA laboratory manager Suneer Jain gives InSequence and Clinical Sequencing News Editor Monica Heger a tour of Illumina's CLIA lab at the company's San Diego headquarters.
Agendia CEO David Macdonald stopped by GenomeWeb's office in New York City and responded to questions from Turna Ray, editor of Pharmacogenomics Reporter, about his company's MammaPrint breast cancer recurrence test and more.
In this video, Adam Bonislawski, editor of ProteoMonitor, caught up with UCSF's Robert Chalkley at the recent Association of Biomolecular Resource Facilities meeting in Orlando, Fl. Chalkley, who is also chair of ABRF's Proteomic Informatics Research Group, discusses the challenge at this year's meeting — identifying post-translationally modified peptides in a complex background — and more.
We dropped by the Feinstein Institute for Medical Research in Manhasset, New York, for a conversation with Peter Davies, director of the Litwin-Zucker Center for the Study of Alzheimer's Disease and Memory Disorders. Davies is heading up a collaboration between the Feinstein Institute, the New York Genome Center, and Illumina that aims to uncover the genetic basis of Alzheimer's disease.
In this video, we sat down with Randall Nelson, research professor at Arizona State University's Biodesign Institute, at the Mass Spectrometry: Applications to the Clinical Laboratory 2012 meeting in San Diego. Nelson speaks about mass spectrometry immunoassay (MSIA) technology and protein heterogeneity, the challenges associated with moving mass spec into the clinic, and more.
This is part two of a conversation with Leigh Anderson, CEO of SISCAPA Assay Technologies, at the Mass Spectrometry Applications to the Clinical Laboratory 2012 meeting in San Diego, California.
This is part one of a conversation with Leigh Anderson, CEO of SISCAPA Assay Technologies, at the Mass Spectrometry Applications to the Clinical Laboratory 2012 meeting in San Diego, California.